文献速递瓣膜病与结构性心脏病

终末期瓣膜性心脏病中的姑息治疗

Palliative care in end-stage valvular heart disease.
PubMed 文献 · Heart · 2017-01-01

瓣膜性心脏病尤其是主动脉瓣病随年龄增长而增多,当手术不可行或风险大于获益时可考虑经导管治疗,但脆弱患者或症状源于其他合并症者可能无法从瓣膜干预中获益。应在干预前评估脆弱性、合并症及患者目标,姑息治疗应贯穿诊断至疾病全程,旨在管理症状并明确患者价值观与治疗目标。

要点

  • 干预前应评估脆弱性、合并症及患者目标,判断瓣膜干预是否真正获益。
  • 姑息治疗应在诊断时启动并贯穿疾病全程,优化健康相关生活质量。
  • 终末期瓣膜病患者姑息治疗研究匮乏,需进一步开展相关研究。

核心结论

  • 姑息治疗应在终末期瓣膜性心脏病患者诊断时即启动并贯穿全程,以管理症状和明确治疗目标。

研究设计与样本

  • 本文为综述,未报告系统检索范围与样本量。

主要发现

  • 瓣膜性心脏病尤其是主动脉瓣病患病率随年龄增长而增加。
  • 手术不可行或风险大于获益时,经导管治疗可能提供有效替代。
  • 脆弱患者或症状由其他合并症导致者可能完全无法从瓣膜干预中获益。
  • 专门针对晚期瓣膜性心脏病患者姑息治疗的研究匮乏。

临床怎么用

  • 干预前应评估脆弱性、合并症和患者目标,以判断瓣膜干预是否合适。
  • 对严重瓣膜病患者应引入姑息治疗,管理症状并明确患者价值观与治疗目标。

局限性

  • 专门针对晚期瓣膜性心脏病患者姑息治疗的研究匮乏,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Valvular heart disease (VHD), particularly aortic valve disease, is prevalent with increasing incidence. When surgery is not possible, or when risks outweigh benefits, percutaneous treatment options may offer effective alternatives. However, procedures may not always go as planned, and frail patients or those whose symptoms are caused by other comorbidities may not benefit from valve intervention at all. Significant effort should be made to assess frailty, comorbidities and patient goals prior to intervention. Palliative care (PC) should play a critical role in the care of patients with severe valve disease. PC is specialised medical care that aims to optimise health-related quality of life by managing symptoms and clarifying patient values and goals of care. It should be implemented at the time of diagnosis and continue throughout the disease course. Because of the paucity of studies dedicated to the provision of PC to patients with advanced VHD, further research is needed.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Steiner JM, Cooper S, Kirkpatrick JN, et al. Palliative care in end-stage valvular heart disease. Heart. 2017. PMID: 28747535. doi:10.1136/heartjnl-2016-310538

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。